Steatosis assessment by Controlled attenuation parameter in patients with compensated advanced chronic liver disease

We have read with great interest manuscript by Piccinni et al. in which they demonstrated significant prevalence of liver steatosis in patients with compensated advanced chronic liver disease (cACLD), previously assumed to decrease in advanced fibrosis, as well as very good performance of Controlled attenuation parameter (CAP) in this cohort of patients (1,2).